Integra Lifesciences Holdings (IART) Long-Term Deferred Tax (2009 - 2026)

Integra Lifesciences Holdings' Long-Term Deferred Tax history runs 18 years deep, the most recent figure standing at $68.1 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 79.11% year-over-year to $68.1 million; the TTM figure through Mar 2026 stood at $68.1 million (up 79.11% YoY), while the FY2025 annual figure was $69.9 million, up 100.02% from the prior year.
• Long-Term Deferred Tax came in at $68.1 million for Q1 2026 at Integra Lifesciences Holdings, down from $69.9 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $109.7 million in Q3 2025 to a low of $34.2 million in Q1 2024.
• A 5-year average of $56.1 million and a median of $48.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax plunged 43.61% in 2022 and jumped 124.95% in 2025, its largest moves.
• Integra Lifesciences Holdings' Long-Term Deferred Tax stood at $46.0 million in 2022, then increased by 0.19% to $46.1 million in 2023, then slipped by 24.21% to $34.9 million in 2024, then jumped by 100.02% to $69.9 million in 2025, then fell by 2.54% to $68.1 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $68.1 million, $69.9 million, and $109.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison